Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 clinical trial of TTC-352

Next Previous
Trial Profile

A phase 2 clinical trial of TTC-352

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TTC 352 (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors TTC Oncology

Most Recent Events

  • 27 Feb 2023 According to Lantern media release, TTC oncology and Lantern Pharma entered a research and development collaboration agreement. Under the terms of agreement TTC Oncology will provide artificial intelligence (AI) insights for recurrent ER+ breast cancer and to identify biomarker on gene signatures to power potential patient selection for this study, characterize TTC-352's mechanism of action and discover additional treatment indications in which TTC-352 may be a potential treatment.
  • 24 Dec 2021 New trial record
  • 20 Dec 2021 According to TTC Oncology media release, preparing to enter phase 2 clinical trials, is innovating safer solutions for the treatment of metastatic breast cancer.TTC Oncology plans to present its phase 2 clinical trial plans at the Biotech Showcase, January 10-19 in San Francisco. The Company will be available for virtual presentation should conditions permit.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top